Epidermal Growth Factor Receptor Mutation Analysis EGFR – Exon 18 19 20 21 Test
Cost: AED 2100.0
Introduction
Epidermal Growth Factor Receptor Mutation Analysis (EGFR – Exon 18, 19, 20, 21) is a genetic test commonly performed in patients with non-small cell lung cancer (NSCLC) to guide treatment decisions. This test detects mutations in specific regions of the EGFR gene.
Test Components
- Paraffin embedded tissue blocks
Price
AED 2100.0
Sample Condition
Tumor tissue
Report Delivery
3-4 days
Method
Sanger Sequencing
Test Type
Genetics
Doctor
Gynecologist
Test Department
Pre Test Information
Epidermal Growth Factor Receptor Mutation Analysis (EGFR – Exon 18, 19, 20, 21) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
Epidermal Growth Factor Receptor (EGFR) mutation analysis is a genetic test that detects mutations in specific regions of the EGFR gene. This test is commonly performed in patients with non-small cell lung cancer (NSCLC) to guide treatment decisions.
The EGFR gene produces a protein that helps regulate cell growth and division. Mutations in exon 18, 19, 20, and 21 of the EGFR gene can lead to the overactivation of the EGFR protein, resulting in uncontrolled cell growth and the development of cancer.
EGFR mutation analysis involves extracting DNA from a patient’s tumor tissue or blood sample. The DNA is then analyzed using techniques like polymerase chain reaction (PCR) or next-generation sequencing (NGS) to identify mutations in the targeted regions of the EGFR gene.
The most common EGFR mutations detected in NSCLC are exon 19 deletions and exon 21 L858R point mutations. These mutations make patients more sensitive to EGFR tyrosine kinase inhibitors (TKIs), a type of targeted therapy for NSCLC. Patients with these mutations are more likely to respond to EGFR TKIs and may have better outcomes compared to those without the mutations.
EGFR mutation analysis can also detect less common mutations, such as exon 18 G719X point mutations and exon 20 insertions. These mutations may have variable responses to EGFR TKIs and may require alternative treatment approaches.
The results of EGFR mutation analysis help guide treatment decisions in NSCLC patients. Patients with EGFR mutations are typically recommended for EGFR TKI therapy as the first-line treatment, while those without mutations may be better suited for other treatment options, like chemotherapy.
Conclusion
EGFR mutation analysis is a genetic test that detects mutations in specific regions of the EGFR gene. This test helps identify NSCLC patients who may benefit from EGFR TKI therapy and guides treatment decisions for improved patient outcomes.
| Test Name | Epidermal Growth Factor Receptor Mutation Analysis EGFR – Exon 18 19 20 21 Test |
|---|---|
| Components | Paraffin embedded tissue blocks |
| Price | 2100.0 AED |
| Sample Condition | Tumor tissue |
| Report Delivery | 3-4 days |
| Method | Sanger Sequencing |
| Test type | Genetics |
| Doctor | Gynecologist |
| Test Department: | |
| Pre Test Information | Epidermal Growth Factor Receptor Mutation Analysis (EGFR – Exon 18, 19, 20, 21) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
Epidermal Growth Factor Receptor (EGFR) mutation analysis is a genetic test that detects mutations in specific regions of the EGFR gene. This test is commonly performed in patients with non-small cell lung cancer (NSCLC) to guide treatment decisions. The EGFR gene is responsible for producing a protein that helps regulate cell growth and division. Mutations in certain regions of the EGFR gene, specifically exon 18, 19, 20, and 21, can result in the overactivation of the EGFR protein, leading to uncontrolled cell growth and the development of cancer. EGFR mutation analysis involves extracting DNA from a patient’s tumor tissue or blood sample. The DNA is then analyzed using various techniques, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS), to identify any mutations in the targeted regions of the EGFR gene. The most common EGFR mutations detected in NSCLC are exon 19 deletions and exon 21 L858R point mutations. These mutations are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), a type of targeted therapy used to treat NSCLC. Patients with these mutations are more likely to respond to EGFR TKIs and may have improved outcomes compared to those without the mutations. Other less common EGFR mutations, such as exon 18 G719X point mutations and exon 20 insertions, may also be detected through EGFR mutation analysis. These mutations have variable responses to EGFR TKIs and may require alternative treatment approaches. The results of EGFR mutation analysis can help guide treatment decisions in NSCLC patients. Patients with EGFR mutations are typically recommended for EGFR TKI therapy as the first-line treatment, while those without mutations may be better suited for other treatment options, such as chemotherapy. In conclusion, EGFR mutation analysis is a genetic test that detects mutations in specific regions of the EGFR gene. This test helps identify NSCLC patients who may benefit from EGFR TKI therapy and guides treatment decisions for improved patient outcomes. |
